Clostridium Difficile News and Research RSS Feed - Clostridium Difficile News and Research

Clostridium difficile is a type of bacterium found in human and animal waste. Clostridium difficile is a common cause of diarrhea that occurs in hospitals. It can also cause diarrhea or other intestinal disorders in patients treated with antibiotics.
Synthetic Biologics' SYN-005 antibody gets FDA Orphan Drug designation for Pertussis treatment

Synthetic Biologics' SYN-005 antibody gets FDA Orphan Drug designation for Pertussis treatment

Synthetic Biologics, Inc., a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that the U.S. Food and Drug Administration has granted Orphan Drug designation to the Company's proprietary SYN-005 monoclonal antibody (mAb) combination for the treatment of Pertussis, more commonly known as whooping cough. [More]
Widespread use of unnecessary antibiotics drives up avoidable healthcare costs

Widespread use of unnecessary antibiotics drives up avoidable healthcare costs

The Centers for Disease Control and Prevention (CDC) and Premier, Inc. have released new research on the widespread use of unnecessary and duplicative antibiotics in U.S. hospitals, which could have led to an estimated $163 million in excess costs. [More]
Antibiotic stewardship programs reduce hospital readmissions due to infection

Antibiotic stewardship programs reduce hospital readmissions due to infection

Antibiotic stewardship programs, which promote the appropriate use of antibiotics in hospitals and other healthcare centers, not only lead to reduction in antibiotic use with reduced adverse events, but also lead to significant savings. [More]
Synthetic announces positive results from final preclinical toxicology study of SYN-004

Synthetic announces positive results from final preclinical toxicology study of SYN-004

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today positive results from its final preclinical toxicology study of SYN-004. [More]
University of Leicester research sniffs out smell of disease in feces

University of Leicester research sniffs out smell of disease in feces

A fast-sensitive "electronic-nose" for sniffing the highly infectious bacteria C. diff, that causes diarrhoea, temperature and stomach cramps, has been developed by a team at the University of Leicester. [More]
Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it will host an Investor Day in New York to discuss the Company's irritable bowel syndrome (IBS) program, including its novel, oral product SYN-010, targeting constipation-predominant IBS (C-IBS). [More]
Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Synthetic Biologics, Inc., a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that its SYN-005 for the treatment of Pertussis will be highlighted at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 5-9, in Washington D.C. [More]
Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013. [More]
Johns Hopkins Medicine, Kaiser Permanente partner to expand ways to deliver quality care

Johns Hopkins Medicine, Kaiser Permanente partner to expand ways to deliver quality care

Kaiser Permanente and Johns Hopkins Medicine today announced plans to strengthen the successful collaboration between the two health care organizations. [More]
Expert guidance offers recommendations for hand hygiene in healthcare facilities

Expert guidance offers recommendations for hand hygiene in healthcare facilities

Expert guidance released today offers updated evidence reviews and recommendations for hand hygiene in healthcare facilities. [More]
NIAID launches CRS3123 Phase I trial to treat C. difficile infection

NIAID launches CRS3123 Phase I trial to treat C. difficile infection

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has launched an early-stage clinical trial of CRS3123, an investigational oral antibiotic intended to treat Clostridium difficile (C. difficile) infection. [More]
Fecal transplantation safe, effective for treating C. difficile in immunocompromised patients

Fecal transplantation safe, effective for treating C. difficile in immunocompromised patients

Researchers have found that fecal transplantation is effective and safe for treating C. difficile in immunocompromised patients. This is the result of a study led by Colleen Kelly, M.D., a gastroenterologist in the Center for Women's Gastrointestinal Medicine at The Women's Medicine Collaborative. [More]

Antibiotic treatment for patients who underwent gall bladder removal does not reduce infection risk

Among patients who underwent gall bladder removal for acute calculous cholecystitis, lack of postoperative antibiotic treatment did not result in a greater incidence of infections, according to a study in the July 9 issue of JAMA. [More]
Covenant and Sartori medical centers deploy TRU-D SmartUVC superbug-slaying robot

Covenant and Sartori medical centers deploy TRU-D SmartUVC superbug-slaying robot

Wheaton Franciscan Healthcare-Iowa is the latest to deploy TRU-D SmartUVC, a 5-foot-5 germ-killing ultraviolet robot equipped with the only infection prevention data collection and reporting software on the market. TRU-D is now in use at Covenant Medical Center in Waterloo and Sartori Medical Center in Cedar Falls, Iowa. [More]
Synthetic Biologics supports SYN-004 C.difficile preventative program with formation of Clinical Advisory Board

Synthetic Biologics supports SYN-004 C.difficile preventative program with formation of Clinical Advisory Board

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today the formation of a Clinical Advisory Board (CAB) to support development of SYN-004, the Company's lead anti-infective product candidate for the prevention of the devastating effects of Clostridium difficile (C. difficile) [More]
Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Like all drugs, antibiotics can have side-effects when administered to people. The most common (and often benign) side effect people experience when taking antibiotics is “associated diarrhea”. This illustrates the fact that antibiotics have an impact on the intestine! [More]
Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Cubist Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration approved SIVEXTRO (tedizolid phosphate) for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI). [More]
Fecal microbiota transplantation works by restoring healthy bacteria and functioning to recipient's gut

Fecal microbiota transplantation works by restoring healthy bacteria and functioning to recipient's gut

Fecal microbiota transplantation --- the process of delivering stool bacteria from a healthy donor to a patient suffering from intestinal infection with the bacterium Clostridium difficile --- works by restoring healthy bacteria and functioning to the recipient's gut, according to a study published this week in mBio-, the online open-access journal of the American Society for Microbiology. [More]
C. difficile bacteria pose major health threat without proper infection prevention in hospitals, homes

C. difficile bacteria pose major health threat without proper infection prevention in hospitals, homes

Without proper infection prevention in hospitals, and now homes, the Clostridium difficile bacteria poses a major health threat, cautions a Case Western Reserve University infection control researcher. [More]
Specific enzyme helps protect good commensal bacteria from harmful effects of antibiotics

Specific enzyme helps protect good commensal bacteria from harmful effects of antibiotics

Researchers from Case Western Reserve University in Cleveland have discovered that populating the gastrointestinal (GI) tracts of mice with Bacteroides species producing a specific enzyme helps protect the good commensal bacteria from the harmful effects of antibiotics. [More]